v3.25.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 11 Months Ended 12 Months Ended
Feb. 13, 2024
Mar. 31, 2024
Mar. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:          
Research and development $ 764,192 $ 904,015 $ 2,907,827 $ 6,315,552 $ 5,288,580
General and administrative 132,941 2,750,922 2,042,704 8,985,351 2,386,469
Total operating expenses 897,133 3,654,937 4,950,531 15,300,903 7,675,049
Loss from operations (897,133) (3,654,937) (4,950,531) (15,300,903) (7,675,049)
Other income (expense):          
Gain from settlement of liabilities with vendors 141,888 3,339,223 8,144
Other expenses     (672,378) (62,182)
Change in fair value of earnout liability 320,117 1,800,000 4,880,000 301,170
Share-based inducement expense (156,250)    
Interest income (expense), net 4,805 (14,434) 850 21,846 138,340
Total other income (expense), net 324,922 1,927,454 (155,400) 7,568,691 385,472
Net loss (572,211) (1,727,483) (5,105,931) (7,732,212) (7,289,577)
Deemed dividends of Series A, B and C Preferred Stock (264,144) (2,508,000)
Deemed dividends related to Series C Common Warrants (84,083) (276,839)
Net loss attributable to common shareholders $ (572,211) $ (1,727,483) $ (5,454,158) $ (10,517,051) $ (7,289,577)
Net loss per common share:          
Basic (in Dollars per share) $ (1,959.63) $ (244.82) $ (31.82)    
Diluted (in Dollars per share) $ (1,959.63) $ (244.82) $ (31.82)    
Weighted average common shares outstanding:          
Basic (in Shares) 292 7,056 171,381 28,972 292
Diluted (in Shares) 292 7,056 171,381 28,972 292
Previously Reported          
Net loss per common share:          
Basic (in Dollars per share) $ (1,959.62)     $ (363.01) $ (24,964.3)
Diluted (in Dollars per share) $ (1,959.62)     $ (363.01) $ (24,964.3)